Clinical trial
Immunotherapy of Melanoma Patients
NCT00112216 · Centre Hospitalier Universitaire Vaudois, Other · Completed
Key facts
| NCT number | NCT00112216 |
|---|---|
| Title | Immunotherapy of Melanoma Patients |
| Official title | Specific Immunotherapy of Skin Melanoma Patients With Antigenic Peptides and Immunological Analysis of the Vaccine Site Sentinel Lymph Node |
| Lead sponsor | Centre Hospitalier Universitaire Vaudois, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Melan-A analog peptide, FluMa peptide, Mage-A10 peptide, SB AS-2 adjuvant, Montanide adjuvant |
| Enrollment | 9 |
| Start date | May 1, 1999 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jun 1, 2005 |
| Last update posted | Apr 24, 2013 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: